Jack W Schuler bought $1000K of Biodesix (BDSX)
Executed Sep 19 2025, disclosed Sep 23 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 23 2025), the stock returned -4.1% (delay-adjusted); from the execution session (Sep 19 2025), -4.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jack W Schuler (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Biodesix, Inc. (BDSX). Across 5 priced purchase filings, the average 21-session return was +10.3% from execution and +8.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of BDSX (100,000 sh across 2 lots, as filed), executed Jan 23.
Healthcare · Biodesix, Inc. operates as a diagnostic solutions company
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→15,000 sh × $24.47
Exec Aug 12
Filed Aug 13 · 5:22 PM ET BDSXPURCHASE Biodesix, Inc. $666K
27,600 sh across 2 lots
Exec Aug 10
Filed Aug 12 · 5:55 PM ET BDSXPURCHASE Biodesix, Inc. $1.2M
100,000 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 9:29 AM ET BDSXPURCHASE Biodesix, Inc. $904K
82,465 sh × $10.96
Exec Jan 22
Filed Jan 26 · 9:28 AM ET BDSXPURCHASE Biodesix, Inc. –
3,488,372 sh · price not plausible
Exec Aug 29 2025
Filed Sep 3 2025 · 4:42 PM ET BDSXPURCHASE Biodesix, Inc. –
4,723,239 sh across 2 lots · price not plausible
Exec May 16 2025
Filed May 20 2025 · 5:30 PM ET BDSXPURCHASE Biodesix, Inc. –
100,000 sh · price not plausible
Exec Nov 21 2024
Filed Nov 22 2024 · 5:30 PM ET BDSXPURCHASE Biodesix, Inc. –
200,000 sh · price not plausible
Exec Nov 20 2024
Filed Nov 21 2024 · 5:30 PM ET